NeuroCog Trials has exceptional scientific depth and clinical expertise across many therapeutic areas. Our science team has published widely in the CNS field and beyond, and our advisors represent some of the best minds in medicine.
Alzheimer’s Disease and Mild Cognitive Impairment
We have reviewed over 20,000 assessments and trained over 2,000 raters for global AD clinical trials. Our eCOA tools are designed for easy adaptation and implementation in MCI and AD populations, and we have dedicated AD specialists with the clinical and operational insight to help navigate challenges and ensure optimal trial performance.
Severe Mental Illness
Our global leadership in schizophrenia is well known throughout industry and academia. We support numerous clinical and neurocognitive endpoints, including assessment of at-risk status, conversion to psychosis, and functional capacity. We also support clinical development programs in bipolar disorder, major depressive disorder, post-traumatic stress disorder, attention-deficit disorder, and other conditions affecting mental health and cognition.
Movement and Motor Neuron Disorders
We have research expertise in Parkinson’s disease (PD), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative conditions. All of our services and resources are tailored to meet the specific needs of each diagnostic population and each clinical trial we support.
Additional Therapeutic Areas
We’ve worked with many other clinical populations to evaluate the cognitive effects of new treatments, including Brain Cancer, Chronic Kidney Disease, and Orphan Diseases.